Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26713425 | 0.85 | STAT3 (0.43) | STAT3CTDSP1SIRT5DHODHKMT2A | |
| SCHEMBL5870519 | 0.81 | STAT3 (0.51) | STAT3CTDSP1SIRT5DHODHKMT2A | |
| SCHEMBL5741905 | 0.79 | STAT3 (0.50) | STAT3CTDSP1SIRT5DHODHKMT2A | |
| SCHEMBL5741906 | 0.79 | STAT3 (0.50) | STAT3CTDSP1SIRT5DHODHKMT2A | |
| SCHEMBL3215490 | 0.78 | STAT3 (0.43) | STAT3CTDSP1SIRT5DHODHKMT2A | |
| SCHEMBL3135862 | 0.76 | STAT3 (0.52) | STAT3CTDSP1SIRT5KMT2AALDH1A1 | |
| SCHEMBL23802602 | 0.76 | TRPV1 (0.56) | DHODHKMT2ATRPV1ALDH1A1MAPK1 | |
| SCHEMBL8058501 | 0.76 | TRPV1 (0.56) | DHODHKMT2ATRPV1ALDH1A1MAPK1 | |
| SCHEMBL8058497 | 0.76 | TRPV1 (0.56) | DHODHKMT2ATRPV1ALDH1A1MAPK1 | |
| SCHEMBL15246442 | 0.76 | TRPV1 (0.56) | DHODHKMT2ATRPV1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | BIOVIE INC. | 2009-08-27 | — | — | US | disclosed |
| US-7524835-B2 | Tetrol steroids and esters | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1223941-B1 | THERAPEUTIC TREATMENTS FOR BLOOD CELL DEFICIENCIES USING SREROIDS | HOLLIS EDEN PHARMACEUTICALS (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-7396827-B2 | Pharmaceutical compositions and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | STAT3 497/4885CTDSP1 1786/4885SIRT5 1038/4885 |
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | STAT3 630/4885CTDSP1 1123/4885SIRT5 1385/4885 |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | HSD3B2, HSD3B1, HSD17B2 | STAT3 863/4885CTDSP1 673/4885SIRT5 2042/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | STAT3 2648/4885CTDSP1 2159/4885SIRT5 1467/4885 |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | HSD3B1, HSD3B2, HSD17B7 | STAT3 784/4885CTDSP1 1506/4885SIRT5 1963/4885 |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | HSD3B1, HSD17B3, HSD3B2 | STAT3 488/4885CTDSP1 1292/4885SIRT5 1847/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | STAT3 605/4885CTDSP1 2134/4885SIRT5 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.